Psoriasis study: Guselkumab
Official title Multi-Center PAMPA Study
ClinicalTrials.gov ID: NCT05004727
What this study is testing
What is Guselkumab?
An investigational injectable medicine being studied as a potential treatment to prevent psoriasis patients from developing psoriatic arthritis. It is designed to block the activity of interleukin‑23 (IL‑23), a protein that drives inflammation in skin and joints.
Also referred to as Tremfya.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether guselkumab stops skin inflammation from causing joint issues. It also checks if the drug reduces signs of joint damage seen on scans.
- Who it's for
- You may be able to join if you have psoriasis and are at high risk for developing joint pain.
- What's involved
- You would get shots of guselkumab or a pretend treatment. You would also have scans to check your joints and muscles.
- Time commitment
- The study lasts two years and includes regular check-ins and scans.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years old or older;
- Both male \& female;
- Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants);
- Willing and able to provide informed consent;
- Fulfillment of HR-PsO criteria (Psoriasis (PsO) patients will meet the definition of HR if they fulfill the following criteria: a) PsO duration \>2...
You likely can't join if
- Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;
- Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);
- RA seropositivity (mid-high RF/ACPA titers);
- Current active malignancy;
- History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development
- Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated...
See the full eligibility criteria
- 18 years old or older;
- Both male \& female;
- Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants);
- Willing and able to provide informed consent;
- Fulfillment of HR-PsO criteria (Psoriasis (PsO) patients will meet the definition of HR if they fulfill the following criteria: a) PsO duration \>2 years and Psoriasis Body Surface Area (BSA) \>3% and positive imaging...
- Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;
- Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);
- RA seropositivity (mid-high RF/ACPA titers);
- Current active malignancy;
- History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development
- Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;
- Known hypersensitivity to the study agent.
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
- New York, New York, United States
- Rochester, New York, United States
- St. John's, Newfoundland and Labrador, Canada
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States; New York, New York, United States; Rochester, New York, United States; St. John's, Newfoundland and Labrador, Canada; Toronto, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.